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Abstract 
 
Background: Posttraumatic stress disorder is a mental illness with severe implications on patient 
quality of life and current treatment options, which are mainly psychotherapeutic, have limited results. 
Recently, MDMA, a highly controversial psychedelic drug, has shown promise as a psychotherapeutic 
enhancer. 
Objective: This review aims to outline existing scientific evidence on the efficacy of MDMA-assisted 
psychotherapy in treating posttraumatic stress disorder. Other important theoretical knowledge and 
empirical evidence regarding the drug will also be presented. 
Method: Using PubMed as the database, a research was conducted targeting articles written in English 
about MDMA’s use in posttraumatic stress disorder’s treatment.  
Results: MDMA is still a drug whose complete means of action, albeit known to be mostly related 
with neurotransmitter metabolism, is not fully understood. Mechanisms involving mood, empathy and 
arousal modulation, as well as neuroplasticity and long-term personality changes have been proposed 
as the reason for its properties as a good psychotherapeutic catalyst, but the true explanation remains a 
matter of scientific debate. Phase 2 clinical trials in patients suffering with posttraumatic stress 
disorder have so far delivered very promising results: MDMA exposed subjects have shown 
significantly better results when compared to placebo exposed cases in all but one study, and its 
application in controlled settings has been considered generally safe, with only one potential serious 
adverse effect ever reported. Phase 3 clinical trials have been justifiably approved and should address 
issues regarding the direct comparison with the current preconized treatment options, the optimization 
of the adverse effects profile, and the reproducibility of the results. 
Conclusion: MDMA-assisted psychotherapy is a very appealing new possibility in the treatment of 
posttraumatic stress disorder. Future studies are necessary for it to become a fully approved therapy. 
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1. INTRODUCTION 
1.1. Background 
 Posttraumatic stress disorder (PTSD) is a common, often chronic, mental illness with severe 
implications on patient quality of life, and has been increasingly recognized as a public health problem [1].  
Treatment options are mainly psychotherapeutic with Prolonged Exposure (PE) therapy being one of 
the most widely accepted treatments [2]. It is based on a “flooding” mechanism, which requires the patient to 
re-live his traumatic experiences decoupled from the actual threat, in order induce an extinction of the fear 
response [3]. Despite being considered the first-line option, PE is very far from being a perfect therapy: 
remission of symptoms after 40 months is only achieved in around 44% of those undergoing treatment [4], 
only 32–66% reach a good level of end-state functioning [5] and only a small minority of veteran patients are 
treated (6.3%) [6] because the emotionally demanding sessions often aggravate the patients’ symptoms before 
they improve [7]. Furthermore, it has high drop-out rates of around 30% [8], which may be explained by the 
detrimental effects that trauma exhibits on the ability to form trusting interpersonal relationships, therefore 
affecting the working alliance between the patient and therapist [9], undermining the efficacy of the treatment. 
Serotonergic agents such as selective serotonin reuptake inhibitors (SSRI) are recommended in treatment 
guidelines [1], but are mainly used to tackle accompanying comorbid disorders [10], with a large proportion 
of patients remaining symptomatic [11] and the benefits of its concomitant application with psychotherapy are 
still matter of debate [1, 12]. Anxiety-reducing drugs were actually proven to be counter-productive in regard 
to long-term recovery [12].  
Recently, ±3,4-Methylenedioxymethamphetamine (MDMA), a highly controversial psychedelic, has 
shown promise as a psychotherapeutic enhancer in the context of PTSD and has been granted Breakthrough 
Therapy Designation by the United States of America’s Food and Drug Administration (FDA).  
 
1.2. Objective 
As phase 3 multi-site trials are currently being conducted, this review aims to outline available 
scientific evidence on the efficacy of MDMA-assisted psychotherapy in treating PTSD. As such, the main 
focus will be directed to clinical trials conducted and published to date of the writing of this review. 
Moreover, other theoretical knowledge and empirical evidence found relevant for a comprehensive 
understanding of the current scientific landscape on the subject will also be addressed.  
 
2. MATERIALS AND METHODS 
 Using PubMed as the database, a research was conducted targeting articles written in English about 
MDMA’s use in PTSD’s treatment. With the goal of obtaining more information on the pharmacology and 
psychological effects related to the drug’s clinical use, and since MDMA has currently no other thoroughly 
studied application, a broader, general association between MDMA and psychotherapy was also researched 
upon. The following query was used: “((MDMA OR 3,4 Methylenedioxymethamphetamine OR N-Methyl-
3,4-methylenedioxyamphetamine OR Ecstasy OR Molly) AND (PTSD OR Post-Traumatic Stress Disorder)) 
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OR ((MDMA OR 3,4Methylenedioxymethamphetamine OR N-Methyl-3,4-methylenedioxyamphetamine OR 
Ecstasy OR Molly) AND (psychotherapy))”. The last date of research was 27/12/2019.  
 The database returned a total 216 articles. One article was excluded for being duplicated. Ten articles 
were excluded for not being written in English. One hundred and nineteen articles were excluded after reading 
of the title and abstract for not being related to the theme. The reading of the remaining 86 articles revealed 
that 35 provided information considered non-relevant or very incomplete and better described in other 
articles. The 51 remaining articles revealed 16 more articles with relevant information. As result, 67 articles 
were included in this review, with the results thematically organized to ensure they were depicted in the most 
intuitive way possible. 
 
3. WHAT IS MDMA 
3.1. Historical Background 
 MDMA is reported to have been firstly synthesized in 1912, although its psychoactive properties 
were still completely unknown [13]. In 1976, Alexander Shulgin discovered MDMA’s psychoactive effect 
and two years later, alongside with his college David Nichols, released a paper [14] in which their findings 
were first described. At around the same time, Shulgin introduced the drug to Leo Zeff [15], the first noted 
psychologist to use MDMA as an adjunct to psychotherapy [16]. The enthusiasm around the therapeutic 
potential of MDMA grew [17], but just as research was taking of, the recreational use of “ecstasy” (tablets 
containing MDMA) in the 1980s prompted authorities to schedule the substance as a drug of abuse [18], 
therefore terminating most of the investigation [19]. By the 1990s, the majority of the studies were focused on 
the harmful effects of ecstasy consumption [20]. 
Shortly after MDMA’s scheduling, the Multidisciplinary Association for Psychedelic Studies 
(MAPS) was created and has been the driving force behind most of the investigation on MDMA and other 
psychedelics. Following 2002’s approval of the clinical plan for trials assessing MDMA’s use on PTSD [21], 
serious research has been finally conducted. 
 
3.2. Pharmacology and Effects 
 MDMA is a racemate composed of equal parts of the S(+) and R(-) isomers [22]. It penetrates de 
blood-brain barrier and establishes complex interactions, mainly with neurotransmitter (NT) receptors. Effects 
usually peak 2h after administration and the drug’s half-life elimination revolves at around 8 h [23]. MDMA 
and its metabolites are primarily cleared by cytochrome P450 (CYP), catechol-O-methyltransferase (COMT), 
glucuronidation, or sulfation isoenzymes, so patients with genetic polymorphisms affecting these enzymes or 
those taking drugs that affect CYP or COMT may have an increased risk of unpredictable or harmful effects 
related to its consumption [24]. It is also a potent CYP2D6 inhibitor, leading to potential interactions with 
CYP2D6 substrates like SSRI’s [24]. 
Even though MDMA’s complete mechanism of action is not fully understood, its distinct effects are 
known to be primarily related to an impact on serotoninergic transmission. This is due to its properties as a 
nonclassical serotonin transporter (SERT) substrate, inducing non-exocytotic serotonin (5-HT) release, by 
5 
 
triggering a reversal of the normal transporter flux [25]. In addition, it also blocks 5-HT reuptake to produce a 
dual extracellular 5-HT raising mechanism [22]. Resulting acute cognitive effects include enhanced mood and 
well-being; happiness; physical and mental relaxation; increased emotional sensitivity and responsiveness;  
increased self-confidence; positively altered evaluation of the self while decreasing concerns about negative 
evaluation by others, heightened openness; extroversion and sociability; the feeling of closeness to other 
people; as well as slight (visual, auditory, and tactile) changes in perception and anxiolysis [26-29]. This 
unique combination has been defined as a “pro-social syndrome” [28], which has led some authors to state 
that MDMA should not be confined to its traditional designation as a psychedelic amphetamine, but belong to 
a new class of psychoactive drugs called “entactogens” [30]. Since 5-HT acts on more than a dozen different 
receptor subtypes, the task of elucidating which of them might be related to each specific effect is rather 
complicated [31].  
 In addition, other NT are also implicated in MDMA’s acute effect, mainly Norepinephrine (NE) and 
Dopamine (DA). This is due to its effects on the NE transporter (NET) and DA transporter (DAT), blocking 
both NT’s reuptake and stimulating their release similar to what happens with 5-HT [31]. Higher extracellular 
NE concentrations have been associated with stimulant-like effects [32], while elevated DA transmission 
might be related to the positive mood modulation [33], but also the deleterious effects like hyperthermia and 
abuse potential [34, 35]. 
Furthermore, MDMA also induces neurohormonal effects, the most important being the stimulation 
of oxytocin release. This is thought to inhibit the autonomic fear response and centrally potentiate complex 
social behaviors involving pair-bonding, sex, affiliative behavior and pro-social feelings [36]. Another 
relevant effect is the potentiation of cortisol release, which relates to elevated mood, increased energy and 
reduced fatigue [37]. 
 
4. MDMA AND PSYCHOTHERAPY 
MDMA’s utility as psychotherapeutic adjuvant starts with its appealing pharmacokinetic profile, 
since the average duration of substance-assisted treatment sessions coincides with its half-life (around 8h) 
[38]. 
Extensive research has been conducted on both the exact properties that might make MDMA a useful 
tool in the context of PTSD’s treatment, and on the drug’s potentially negative effects on exposed individuals. 
 
4.1. Benefits 
The reason why MDMA is an efficient psychotherapeutic adjuvant in PTSD still remains a matter of 
research, with multiple proposed mechanisms that, even though likely interconnected, will be presented in 
two separated topics for the sake of better explanation. 
 
4.1.1. Short-term benefits 
As previously mentioned, the “flooding” process, in which PE therapy in PTSD is based on, requires the 
patient to relieve the actual memory, possibly leading to an acute elevation of the very own symptoms the 
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therapy wishes to reduce. This fine line between treating and hurting is one of the main reasons why PE 
shows limited results, and here is where pharmacological enhancement by MDMA comes to play by. [3, 12] 
Firstly, while the improved mood state has a predictable positive modulation effect on the present 
perception of the memories, MDMA might also have a selective effect on emotional memory retrieval, 
altering the recollection of details specifically associated with negative and positive stimuli [39], therefore 
attenuating the intensity of the experienced fear during the session and allowing for a better trauma 
exploration. 
Furthermore, since trauma impairs the patient’s ability to form a trusting relationship with the therapist, it 
is hypothesized that the heightened sociability allows a better “working alliance” [23]. In fact, evidences 
shows that MDMA-exposed individuals produce greater numbers of empathic (regarding others' emotions), 
entactic (requesting or appreciating physical touch), and ensuic (describing a change in their sense of 
themselves) utterances in clinical settings [40]. This effect might be explained by an altered conceptualization 
of “social reward” (placing more emphasis on the direct relationship with interacting partners) [41], a 
decrease in the perception of social rejection [42] and a selective modification of the socially-related stimuli 
processing, slowing the perception of negative emotions, and potentiating the response to positive ones, 
leading to an increase in the comparative value of social contact and closeness with others, as opposed to non-
social stimuli [43, 44].  
Finally, MDMA’s elevation of DA and NE, as well as the induction of cortisol release, are thought to 
produce a combined stimulant effect that increases patients’ motivation to engage in therapy without feeling 
overwhelmed by the arising emotions [45], setting up an “optimal arousal zone” where patients are 
appropriately alert and motivated to engage in the psychotherapeutic process, but not overly stimulated as to 
be hypervigilant [5]. 
 
4.1.2. Long-term benefits 
Heightened fear response to environmental stimuli is shown to be reflected in neuroimaging as 
hyperactivity in the amygdala and hypoactivity in the prefrontal cortex [36]. Recent functional magnetic 
resonance imaging (fMRI) studies have shown that, in healthy volunteers, MDMA causes a modulation 
of spontaneous brain activity resulting in augmented activations in response to favorite memories in some 
regions, and attenuated activations to worst memories in others [46, 47]. The alteration of the crosstalk 
between these areas could be the neural correlate of an higher mismatch between the memory trace and 
present happenings experienced by MDMA exposed patients which, in the event of a potentiation of 
neuroplasticity, may allow for new and less stressful emotional content to be overlaid on these circuits, 
modifying the existing memory, and amplifying both treatment’s short and long-term therapeutic effects [36, 
48]. 
In a mouse model trial, MDMA exposure has shown to enhance both long-term fear extinction and 
the transcription of brain-derived neurotrophic factor (BDNF), a compound that plays a crucial role in 
promoting  hippocampal synaptic plasticity and regulating memory reconsolidation [49], which might allow 
for older memories to be “reconfigured”. Interestingly, the same authors reported in a later study that chronic 
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and acute administration of a SSRI blocked this positive effect on fear memory extinction, a relevant finding 
given the large number of PTSD patients currently treated with SSRI drugs [50]. However, a recent trial 
conducted using Dark Agouti rats as opposed to mice, reported MDMA to be more prone to inhibit rather than 
enhance fear-extinction learning [51], an inconsistency that accentuates the need for more research. 
Nevertheless, genetic expression in the same Dark Agouti rats strain seems to support this mechanism, as a 
single dose of MDMA has been reported to upregulate various gene sets related to neuroplasticity and 
synaptic formation/reorganization in the frontal cortex, while downregulating genes related to memory and 
cognition in the hippocampus [52].  
Another mechanism possibly related with the long-term benefits is based on the therapy’s effect on 
personality, since evidence suggests that MDMA assisted-psychotherapy may induce long-term changes in 
patients’ traits associated with trauma, such as a boost in openness (increased seeking out of new experiences, 
being more prone to self-examination, more imaginative, and more sensitive to inner feeling and the feelings 
of others [53], an hypothesis which indicates that MDMA’s clinical application may be able to shift aspects of 
personality assumed to be relatively stable constructs throughout much of adulthood [53, 54].  
 
4.2. Potentially Harmful Effects 
Various deleterious effects related to “Ecstasy’s” recreational usage have been reported in the 
literature. Though these effects might, at first, seem important for the aim of this paper, since the vast 
majority of research concerning “Ecstasy” appears to be inapplicable for the strict establishment of risks 
concerning the potential usage of MDMA in clinical settings due to purity issues [26], uncontrolled polydrug 
consumption [55], and environmental differences [27], the two concepts are not considered interchangeable 
and a review on “Ecstasy” will not be conducted. 
Reported negative psychological effects demonstrated in human studies with MDMA include 
depersonalization; dissociative symptoms; lack of energy; depression; sleep disturbances; and transient 
deficits in immediate and delayed recall, working memory, selective attention and associative memory [22]. 
Furthermore, some evidences of neurobiological damage have been reported in rat models, such as an 
oxidative stress-related persistent decrease in 5-HT neurotransmission [22], and, in previously stressed 
subjects, a significant downregulation of gene categories related to tissue regeneration, axon ensheathment, 
and cytokine receptor interaction [56] 
More theoretical concerns are also worth mentioning. Firstly, since the main mode of operation of 
MDMA’s assisted psychotherapy consists on stimulating the release of difficult and stressing feelings and 
memories, then there might be some clinical scenarios in which MDMA-induced experiences may prove 
difficult to control and potentially more stress-inducing to the patient, especially if the therapists are 
inexperienced [57]. Furthermore, patients might misattribute therapeutic gains to medication, minimizing the 
importance of maintaining the improvements through psychological changes, leading to a greater relapse risk 
[26]. This relates to the potential risk of patients seeking illicit supplies of MDMA after experiencing 
therapies with good results, which naturally accommodates the psychological consequences inherent to all 
non-medically advised psychoactive drug consumption. In addition, psychiatrically vulnerable patients may 
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also be in danger of experiencing unexpected and undesired symptoms when exposed to a psychedelic drug 
[57]. 
 
5. CLINICAL TRIALS 
 The most widely accepted guide for conducting MDMA-assisted psychotherapy was published by 
MAPS [58] and is regularly updated. It follows the usual framework normally applied in other Psychedelic-
assisted psychotherapies (PAP), generally including drug-free sessions before (preparatory) and/or after 
(integrative) drug sessions [59]. 
All recent MDMA‐assisted psychotherapy trials were conducted meeting rigorous standards for drug 
development, regulated by the FDA or equivalents, and overseen by Institutional Review Boards (IRBs). 
Moreover, in the United States, due to the Schedule 1 status of MDMA, compliance with the Drug 
Enforcement Administration (DEA) and state‐level controlled substance review committees is required, 
placing these studies in the most regulated area of drug development [60]. 
In all trials, the primary outcome measure was the variation in CAPS (Clinician-Administered PTSD 
Scale), with clinical response being generally defined as a >30% decrease on the score. Most studies included 
two stages, with the second one consisting of an open-label crossover, in which control subjects also had the 
opportunity to receive an active dose of MDMA [10, 23, 54, 61]. Long-term follow-ups (LTFU), generally up 
to one year, intended to evaluate the persistency of the effects over time were also performed. Neurocognitive 
testing, blood pressure and temperature monitoring were used to assess adverse effects. 
To this day, 5 clinical trials testing MDMA’s efficacy as a psychotherapeutic adjuvant in the context 
of PTSD’s treatment have been conducted. 
 
5.1. Bouso et al. (2008): [62] 
The first fully approved placebo-controlled clinical trial. The main objective was to assess the safety 
of a single psychotherapy session on 29 chronic PTSD sufferers using a wide range of symptom and 
comorbidity scales. 
Political pressure resulted in only 6 subjects being treated before the sudden termination of the study. 
Despite the abrupt conclusion, no adverse effects were reported. 
 
5.2. Mithoefer et al. (2011): [23] 
Published in 2011, this was the first randomized, double-blind, placebo-controlled trial conducted in 
the United States. Twenty subjects with chronic refractory posttraumatic stress disorder were randomly 
assigned to psychotherapy with an inactive placebo, or with a full 125mg dose of MDMA (with the possibility 
of an additional 65mg 2h later). 
Decreases in CAPS scores from baseline and rates of clinical response were significantly greater for 
the group that received MDMA than for the placebo group (67.8% versus 25.8%), with the latter showing 
similar magnitude improvements after the open-label crossover. There were no reports of serious drug-related 
adverse events or neurocognitive effects. The LTFU [63] concluded there were no statistical differences 
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between mean CAPS scores at the given time and those obtained at study exit, which indicated that the 
benefits persisted over time. 
Despite the small sample size, low gender and ethnic differences between patients (majority female 
and all Caucasian), and the inefficacy of the double-blinding since both the patients and the therapists could 
tell if the subject had taken MDMA, this was the first study that firmly highlighted the therapeutic potential of 
the drug as a psychotherapy catalyst. 
 
5.3. Oehen et al. (2013): [10] 
A few years later, in Switzerland, Oehen et al. (2013) conducted the first active placebo trial. The 
study enrolled 12 patients with treatment-resistant PTSD for therapy with either low-dose (25 mg, plus 12.5 
mg as supplemental dose) or full-dose MDMA (125 mg, plus 62.5 mg as supplemental dose). The 
Posttraumatic-Diagnostic Scale (PDS), a self-reporting measure to access the presence of PTSD symptoms, 
was used as a secondary outcome measure. 
After stage 1, a significant PDS improvement was reported in the full-dose group relatively to the 
active placebo group, however the results were not as impressive as those published 2 years earlier by 
Mithoefer et al. (2011) regarding CAPS reduction, with no findings of statistically significant differences 
between the two groups. Nevertheless, clinical response was reported in 50% of the subjects in the full-dose 
group. Interestingly, three sessions were reported to exhibit significantly superior effects than only two. 
The active placebo improved the blinding when compared to the inactive one used in Mithoefer’s 
study but turned out to be less well tolerated psychologically in three of the control subjects, due to what the 
authors refered to as a “state of partial activation”, consisting of spontaneous recall, but without maximum 
fear reduction. Despite this counter-therapeutic effect, no serious adverse reactions were reported in any 
group. 
Persistent benefits were once again reported in the LTFU, however some subjects had begun a new 
therapy during that period, which undermines the conclusions about the long-term effects. 
 
5.4. Mithoefer et al. (2018): [54] 
More recently, Mithoefer et al. (2018) published another trial, this time including 26 military 
veterans and first responders with CAPS scores >50, randomized into three different dose groups: an active 
placebo control of 30mg, a 75mg group and a 125mg group. 
Contrary to the Oehen study, the trial showed higher MDMA doses to have very significant 
beneficial results when compared to lower ones, both at the primary endpoint, in which the 125 mg and 75 
groups had mean changes in CAPS of –70.8% and –49.4% versus –13.0 observed in the 30 mg group, and 
after the open-label crossover, in which the original 30mg group showed similar improvements. This time, no 
counter-therapeutic effect in the low-dose groups was verified. 
Despite the treatment being once again reported as generally well tolerated, one severe cardiac 
adverse effect possibly related to MDMA’s administration was described. Even though it was conveniently 
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detected, and the subject recovered without evidence of any vascular or structural cardiac disease, it raises 
some concerns regarding the drug’s cardiovascular safety. 
After the LTFU the gains were clearly maintained, not only in terms of CAPS score (mean CAPS 
score of 38.8 versus 87.1 at baseline), but also in the personality traits associated with trauma, reinforcing the 
hypothesis that MDMA clinical application might be capable of long-term personality changes. 
 
5.5. Ot’alora et al. (2018):[61] 
The most recent study was conducted by Ot’alora et al. (2018) and was the first to assess the efficacy 
and safety of MDMA-assisted psychotherapy across multiple therapy teams, with subjects randomized into 
two active dose groups of 100mg and 125mg, and one active placebo group of 40mg. 
CAPS score reduction was greater in the active groups, even with different therapy teams, an 
important finding giving that multi-site Phase 3 trials are due to begin shortly. This time, however, outcomes 
were analyzed according to intent-to-treat (ITT) versus per-protocol (PP) method, and statistical significance 
was only attained in the latter set. This indicates that, not only in this study but also in the previous ones, 
withdrawals may have an important implication on the overall outcome. Three sessions were found to be 
more efficient than two in the 100 and 125mg groups, but not in the 40mg group. No significant adverse 
effect was reported. 
The gains were maintained over the LTFU after all groups had received active doses of MDMA, with 
76% of all the individuals not meeting the criteria for a PTSD diagnosis, which is consistent with previous 
findings regarding the therapy’s long-term benefits. 
 
6. DISCUSSION 
Novel therapy research, especially for conditions, like PTSD, whose approved options show limited 
results, is always welcome. Nonetheless, reported clinical benefits that seem too good to be true must be 
looked upon with a careful balance between enthusiasm and skepticism, a stance that may prove particularly 
hard to maintain when research is conducted on substances with a history as controversial as psychedelic 
drugs. Furthermore, their suggested ability to perturb consciousness in a way that a single acute exposure 
might elicit immediate and lasting changes to the patients’ psyche [64] may raise relevant ethical questions 
regarding their clinical use. However, this also means they are a compelling tool for understanding  the 
connectivity of the brain and could represent a new paradigm in the way medicine understands and treats 
psychiatric illnesses [64]. MDMA-assisted psychotherapy for PTSD’s seems to capitalize on this exact 
property, as treatment does not simply symptomatically “paper over” the cracks of trauma, but tackles it’s 
very own neuronal foundation [65]. 
While MDMA’s pharmacological properties and mechanisms of action still need additional research 
to be completely understood, clinical trials have supported the safety of MDMA in controlled settings, and 
have been consistent with the imperative need to completely separate its concept from that of “ecstasy” [10, 
23, 54, 61, 62]. All trials but one [10] reported significant clinical efficacy, which legitimizes future research 
and the Breakthrough Therapy Designation granted by the FDA. So far, it appears the current full-dose of 
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125mg is the most efficient application, with supplemental dosage not showing consistent benefits and lesser 
measures sometimes exhibiting deleterious effects [10]. Three therapeutic sessions have, in some cases, 
demonstrated better results than two [10, 61] 
A preliminary meta-analysis published in 2016, thus including only 3 out of the 5 trials conducted so 
far, reported that MDMA-assisted psychotherapy was superior to PE when evaluated by clinician-observed 
outcomes, by patient self-report outcomes and by drop-outs [66]. However, the type of psychotherapy 
currently administered with MDMA is none of the empirically supported exposure-based treatments for PTSD 
[1]. Therefore, a direct comparison between MDMA-assisted psychotherapy and the standard-of-care PE with 
SSRI therapy is still lacking and should be addressed on subsequent clinical trials [24]. 
The fact that one of the trials demonstrated the efficacy of the therapy in war veterans, one of the 
most treatment-resistant patient groups, is also encouraging. Nevertheless, as demonstrated by the most recent 
study [61], drop-out rates, a central reason for the failure of current psychotherapeutic options, have also 
shown to influence the effectiveness of MDMA-assisted psychotherapy, an issue that must be further 
scrutinized on future studies. 
 Despite the overall safety profile of clinical MDMA’s application looking relatively stable 
throughout all trials, the serious cardiac event verified in one of them [54] raises important questions 
concerning its hemodynamic effects on patients suffering from cardiovascular conditions. 
Furthermore, patients receiving SSRIs, which are commonly used in psychiatry and that 
pharmacologically block the effects of MDMA, might experience lackluster results and even some undesired 
effects, like those observed in the low-dose group of the Oehen et al. (2013) trial. In fact, lower MDMA doses 
have recently been reported to have less “good drug effects” than higher ones [67]. This turns the risk-benefit 
evaluation of removing the SSRI to potentiate the therapy versus maintaining it to prevent the relapse of 
depressive symptoms, a focal point of patient assessment. Additionally, MDMA’s effect on CYP, COMT and 
CYP2D6 must also be taken into consideration, since it may underlie potentially unpredictable effects. 
 A new possible way to minimize negative effects based on MDMA’s racemic nature has been 
proposed. Findings suggest that R(-)-MDMA may be a clinically superior drug in comparison to the 
commonly used racemic MDMA, maintaining the therapeutic effects while reducing the adverse ones [34, 
35]. This new possibility should be kept in mind for future trials. 
Also noteworthy is the fact that nearly all clinical trials so far have been conducted with the direct 
involvement of MAPS personnel. The preponderance of this association in the drug’s study is undeniable, 
and, without its existence, MDMA would most certainly still be regarded as nothing more than the central 
compound of a street drug. However, and since the only study that took part outside the United States without 
their firsthand involvement ended up with significantly less thrilling results [10], further investigations should 
have the freedom to analyze and report their conclusions without the intervention of MAPS, for the sake of 
better and stronger scientific evidence. 
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CONCLUSION 
MDMA-assisted psychotherapy surely is a promising new therapeutic option for PTSD. Current 
findings are consistent with its overall safety and the outcome results completely justify the conduction of 
more research. However, issues regarding its direct comparison to current preconized treatment options, 
optimization of the adverse effects profile, and reproducibility of the results still need to be attended so it can 
become a fully approved treatment. Phase 3 clinical trials will provide invaluable and decisive information on 
the matter. 
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